Analytica Ltd

ABN 12 006 464 866

Appendix 4D

Half Year Report

For the 6 months ended December 2021(current period)
And the previous corresponding period 6 months ended 31 December 2020

Results for announcement to the market

Revenue from ordinary activities:	Down	100%	to	$109
(Loss) from ordinary activities after tax attributable to members:	Up	305%	to	(1,373,117)
Net (Loss) for the period attributable to members:	Up	305%	to	(1,373,117)

	Current period	Previous corresponding period
Net tangible asset backing per ordinary share	(0.01) cents	(0.01) cents
Basic earnings/(loss) per share	(0.030) cents	(0.013) cents

An explanation of the result of the current period is set out in the Directors Report contained in the attached audit reviewed half-year Financial Report

Full financial details of the Company are also contained in the attached half-year Financial Report. Audit review is currently underway.

Dividends: It is not proposed that any dividend will be paid. No dividends were paid in the previous corresponding period.

Analytica Limited

ABN 12 006 464 866

CONSOLIDATED INTERIM FINANCIAL STATEMENTS

HALF YEAR ENDED 31 DECEMBER 2021

Table of Contents

Table of Contents

Directors Report

General information

Information on directors

The names, qualifications, experience and special responsibilities of each person who has been a director during the year and to the date of this report are as follows. Directors have been in office since the start of the year to the date of this report unless otherwise stated.

Dr Michael Monsour

MBBS-HONS, FACRRM, FAICD

Chairman of the Board (appointed 28 June 2004)

Dr Michael Monsour is a Medical Practitioner with extensive interests in Queensland medical and dental centres. Michael Monsour graduated from the University of Queensland in 1977 in medicine with honours. He operates a medical management company, which provides management support to medical and dental practitioners. He is the principal of Godbar Software (established 1988) which is one of the leading software developers of Occupational Health, Safety and Medical Accounting software packages in Australia.

Dr Peter B. Corr.

Non-Executive Director (appointed 23 May 2017)

Received his doctorate from Georgetown University School of Medicine.

Dr. Corr has extensive experience in the discovery and development of medicines as well as the sale of assets to major multinational corporations. Dr. Corr co-founded and is Managing General Partner of Auven Therapeutics, a private equity firm pursuing a life science investment strategy where products are acquired, developed and then sold to multinational pharmaceutical firms. Dr. Corr was previously a Professor of Medicine and Pharmacology at Washington University for 18 years. He then joined Searle as Senior VP of Discovery Research, and subsequently was President of Research and Development at Warner Lambert / Parke Davis and then President, worldwide Development at Pfizer, and Corporate Senior Vice President of Science and Technology at Pfizer.

Mr Ross Mangelsdorf

B.Bus, FCA, CTA, MAICD

Executive Director (appointed 7 October 2008)

Mr Mangelsdorf performs the function of Chief Financial Officer.

Mr Mangelsdorf is a Director/partner of a chartered accounting firm for 40 years. He works with SME production, manufacturing and retail firms assisting with business, taxation and management services.

Principal activities and significant changes in nature of activities

The principal activities of the Group during the year were:

- The development of strategies on commercial sales of PeriCoach;
- The development of intellectual property of medical device and mobile health application in relation to patents and systems in the pelvic floor exercise field (PeriCoach);
- The development of intellectual property in the medical device field in relation to patents in the burette field (AutoStart Infusion System);
- The development of strategies for commercial sales of burette products;
- There were no significant changes in the Group's principal activities during the half year.

Operating results and review of operations for the half year

Operating results

The consolidated loss of the Group for the half year ended 31 December 2021 amounted to $1,373,117 (December 2020: loss $449,565), after providing for income tax. For the 6 months to December 2021 there is an overall increase in expenses of $144k compared to December 2020. This increase was predominantly attributable to an increase in Research and Development of $31k, an increase in Administration of $48k, an increase in Marketing $81k. Income decreased by $780k, with R&D Tax incentive not received as yet and no government covid business support.

Review of Operations

PeriCoach

Executing the commercialisation strategy for the PeriCoach is focused on the following milestones:

- Building ‘best-in-class’ conservative treatment for pelvic floor conditions, with a particular focus on urinary incontinence.
- Validate and extend clinical credibility and effectiveness of PeriCoach.
- Confirming market acceptance while creating a positive sales environment.
- Securing a competitive partnering agreement with a major multinational company with the resources to make the PeriCoach a global success.

Manufacturing Capability

Analytica's commercialisation process for the PeriCoach system to date has followed the path of R&D, product development, regulatory clearances, and conducting market research. During this phase Analytica has outsourced manufacturing of the product.

With positive progress having been achieved on its commercialisation activities, such as the distribution agreement in the Middle East across 10 countries and the JV in China, Analytica has conducted a strategic review of its manufacturing strategy in contemplation of higher prospective demand for the PeriCoach product in North America and Europe currently being pursued.

Analytica has taken the decision to develop its own manufacturing capability and become the regulatory manufacturer of record for the PeriCoach product.

The benefits of bringing the PeriCoach product under Analytica’s control include:

Better supply chain management and regulatory compliance - being better able to manage delays in global supply chains and restricted travel during the COVID-19 pandemic and comply with regulatory requirements (including new certifications and responsibilities imposed on manufacturers following recent rule changes in Europe and Australia regarding software and medical devices);

Meet potential demand from distribution networks - being better able to meet prospective demand for the PeriCoach product for Australian sales and export to the Middle East, European and U.S. markets, with appropriate clearances; and

Market re engagement - leveraging the 2020 published clinical trial results from the University of New Mexico with a clinical trial and peer reviewed publication and subsequent published health economic manuscript, Analytica will be well positioned to start re engaging with the market. For example, it would provide the ability to re commence direct to consumer sales and continue to pursue deals with public health systems and health insurers to address the enormous Women's Health issues of rehabilitation of post-natal mother's and treatment for post-menopausal women to prevent or delay their entry into residential aged care.

An internal manufacturing capacity will require the establishment of an ISO 13485 certified, an US QSR compliant facility of our own.

Analytica has presented a detailed, stage manufacturing expansion plan over five years to the Queensland government which has agreed to provide funding over the project under an AQIAF agreement.

Analytica’s proposal to the Queensland government involves establishing a headquarters in Maryborough, QLD comprising manufacturing, warehousing, a customer support centre, a data centre, administration and training support for the production of the PeriCoach eHealth system.

Initially, Analytica will accept supplied components and perform final assembly, quality control testing, packaging and product release. As volumes increase the plan allows for plastic and silicon moulding to be brought in house, and at full implementation, electronics manufacturing.

Analytica’s CEO and COO are experienced managing medical device manufacturing and have been adapting the company's quality management system for in house manufacturing over the last 15 months. Analytica has pre arranged for a notified body to conduct an ISO13485 audit of Analytica’s facilities and quality system.

The AQIAF programme was established in 2016 by the Queensland government to provide financial incentives to attract projects assessed to provide significant economic benefits to QLD. AQIAF specifically aims to drive job creation, regional growth, increased innovation and technology and supply chain development. Analytica’s plan meets all these objectives.

Analytica’s directors wish to express appreciation for the support and confidence of the Queensland government.

Grant payments are made retrospectively on completion of agreed milestones and there is no obligation on Analytica to continue the project should circumstances change, noting the Queensland government has the right to terminate the grant if Analytica is not able to meet the agreed milestones.

The AQIAF grant is being provided on standard AQIAF terms and conditions. In addition, various project specific grant pre conditions must be met within 12 months including securing a site in Maryborough, entering into fit out contracts, securing project funding for the first three years (including performance bank guarantees to the Queensland government), an approved funding plan for the balance of the project, continued TGA approval for the PeriCoach product, an approved workforce development plan, approved marketing, distribution and sales arrangements. Analytica is working constructively towards satisfaction of these preconditions but there is no guarantee or assurance that these preconditions will be satisfied either at all or on terms and conditions satisfactory to the Queensland government or Analytica or that the grant funding will be made available.

Intellectual Property

On the 9th November 2021 US patent 11,166,661 “Intra vaginal device to aid in training and determining muscle strength” concerning the arrangement of force sensors in pelvic floor exercise devices was granted. This patent will expire on 9th of January 2032 provided all renewal fees are paid.

The US is the biggest medical device market in the world and this patent gives Analytica an additional level of intellectual property protection in the market for pelvic floor strengthening, control and rehabilitation. The arrangement of the force sensors is a key technology allowing the PeriCoach to target the pelvic floor muscles that matter, unlike most perineometers that measure intra-abdominal pressure, which is only indirectly related to the pelvic floor muscle activity.

The PeriCoach technique feedback functionality uses inputs from the uniquely position PeriCoach force and movement sensors to assess the strength and technique used in contracting the pelvic floor muscles. PeriCoach movement sensing technology was granted US Patent 10,966,654 on the 6th of April 2021.

This invention has also been granted patent protection in Australia, China, and Japan. Analytica also has patent protection granted for the PeriCoach motion sensor in Australia and the US. Both patent families have applications pending in other jurisdictions including Europe.

Financial Review

Financial position

The net assets of the Group have decreased by $1,373k from 30 June 2021 to a $718k at 31 December 2021.

The Company's immediate short term working capital requirements are being provided by the Company's major shareholder. There are a number of commercial initiatives that are advanced but remain incomplete and confidential. The Company believes that if these commercial initiatives can be completed, the Company will have a commercial basis to seek additional equity funding to meet its business objectives.

Events after the reporting date

No matters or circumstances have arisen since the end of the half year which significantly affected or could significantly affect the operations of the Group, the results of those operations or the state of affairs of the Group in future financial years.

Future developments and results

Continue the commercialisation strategy for the PeriCoach namely:

- Executing the commercialisation strategy for the PeriCoach is focused on the following milestones:
- Building 'best-in-class' conservative treatment for pelvic floor conditions, with expansion from the current focus on urinary incontinence to include pelvic organ prolapse, a condition which affects up to 10% of all women at some stage of their lives.
- Validate and extend clinical credibility and effectiveness of PeriCoach
- Confirming market acceptance while creating a positive sales environment
- Securing a competitive partnering agreement with a major multinational company with the resources to make the PeriCoach and AutoStart/AutoFlush burette global success's.

Auditors independence declaration

The auditor's independence declaration in accordance with section 307C of the *Corporations Act 2001* for the half year ended 31 December, 2021 has been received and can be found on page 8 of the interim financial report.

This report is signed in accordance with a resolution of the Board of Directors.

Dr Michael Monsour

Director

Mr Ross Mangelsdorf

Director

Dated this 23 February 2022

Key Management and Staff

Geoff Daly, Chief Executive Officer

Mr Daly is a Chartered Biomedical and Mechanical Engineer with 25 years of professional engineering experience, the last 20 in the medical device industry. Mr Daly has expertise in design processes, quality systems, and business system improvement, and is trained in the use of Six Sigma tools. He has extensive hands-on design experience of product development in FDA QSR and ISO 13485 environments in some of Australia's largest and smallest medical device companies.

Chelsea Cornelius – Product Development and Operations Manager

Chelsea started at Analytica in 2008 and has been a key developer of the PeriCoach. Chelsea has a double degree of Arts (Cultural Studies) and Engineering (Mechanical; Hons) at Swinburne University, and a Masters of Biomedical Engineering at Melbourne University. In 2016 Chelsea received the Medical Technology Association of Australia Outstanding Achievement Award.

Bentleys
THINKING AHEAD

AUDITOR'S INDEPENDENCE DECLARATION
UNDER SECTION 307C OF THE *CORPORATIONS ACT 2001*

TO THE DIRECTORS OF ANALYTICA LIMITED

I declare that, to the best of my knowledge and belief, during the half year ended 31 December 2021 there has been:

i. no contraventions of the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the review; and

ii. no contraventions of any applicable code of professional conduct in relation to the review.

Bentleys.

Bentleys Brisbane Partnership
Chartered Accountants

Ashley Carle
Partner

23 February 2022

Consolidated Interim Statement of Profit or Loss and Other Comprehensive Income

For the Half Year Ended 31 December 2021

Continuing operations	**Note**	**Dec-21 $**	**Dec-20 $**
Sales Revenue		**2,882**	-
Cost of Sales		**(1,323)**	-
Gross Profit		**1,559**	-
Grant Income		**-**	653,395
Government Business Support		**-**	119,600
Investment revenue		**308**	3
Profit/(Loss) on Sale of Equipment		**(1,258)**	-
Royalty Income/(Reversal)		**(1,823)**	8,327
Administration expense	**2**	**(500,263)**	(452,496)
Depreciation, amortisation and impairments	**2**	**(7,015)**	(3,344)
Finance expenses	**2**	**(36)**	(25,531)
Foreign Currency Gains and Losses		**(1,991)**	(3,721)
Investments Fair Value Adjustment		**8,358**	2,419
Marketing expenses	**2**	**(118,346)**	(37,611)
Occupancy expenses		**(9,457)**	(2,564)
Patent maintenance expenses	**2**	**(13,420)**	(9,212)
Research and development expense	**2**	**(729,733)**	(698,830)
Profit/(Loss) before tax		**(1,373,117)**	**(449,565)**
Income tax expense		-	-
Net Profit/(Loss)		**(1,373,117)**	**(449,565)**
Earnings per share			
Basic/diluted earnings per share (cents)		**(0.030)**	**(0.013)**

Consolidated Interim Statement of Financial Position

As at 31 December 2021

Assets	Dec-21 $	Jun-21 $
Current Assets		
Cash and cash equivalents	**572,168**	1,890,683
Inventories	**115,098**	177,802
Prepayments	**57,613**	114,836
Trade and other receivables	**16,296**	18,934
Total Current Assets	**761,175**	**2,202,255**
Non-current Assets		
Intangible assets	**420,017**	384,092
Other financial assets	**21,939**	13,581
Property, plant and equipment	**18,760**	8,690
Total Non-current Assets	**460,716**	**406,363**
Total Assets	**1,221,891**	**2,608,618**
Liabilities		
Current Liabilities		
Employee benefits	**304,571**	263,785
Short-term provisions	**56,405**	70,295
Trade and other payables	**127,405**	171,448
Total Current Liabilities	**488,381**	**505,528**
Non-Current Liabilities		
Provision for Long Service Leave	**14,783**	11,246
Total Non-Current Liabilities	**14,783**	**11,246**
Total Liabilities	**503,164**	**516,774**
Net Assets	**718,727**	**2,091,844**
Equity		
Current Year Earnings	**(1,373,117)**	(1,507,405)
Issued capital	**107,383,796**	107,383,796
Reserves	**252,020**	900,065
Retained Earnings	**(105,543,972)**	(104,684,612)
Total Equity	**718,727**	**2,091,844**

Consolidated Interim Statement of Changes in Equity

For the Half Year Ended 31 December 2021

Half Year Ended 31 December 2021

	Ordinary Shares $	Retained Earnings $	Option Reserve $	Total $
Balance at 1 July 2021	**107,383,796**	**(106,192,017)**	**900,065**	**2,091,844**
Profit (loss) attributable to members	**-**	**(1,373,117)**	**-**	**(1,373,117)**
Shares issued during the year	**-**	**648,045**	**(648,045)**	**-**
Transaction costs	**-**	**-**	**-**	**-**
Balance at 31 December, 2021	**107,383,796**	**(106,917,089)**	**252,020**	**718,727**

Half Year Ended 31 December 2020

	Ordinary Shares $	Retained Earnings $	Option Reserve $	Total $
Balance at 1 July 2020	103,867,798	(104,726,230)	852,188	(6,244)
Profit (loss) attributable to members	-	(449,565)	-	(449,565)
Options expensed/ (reversed)	-	41,619	(41,619)	-
Transaction costs	-	-	-	-
Balance at 31 December, 2020	103,867,798	(105,134,176)	810,569	(455,809)

Consolidated Interim Statement of Cash Flows

For the Half Year Ended 31 December 2021

	Dec-21 $	Dec-20 $
CASH FLOWS FROM OPERATING ACTIVITIES:		
Receipts from customers	**2,882**	-
Receipts from grants	**-**	653,395
Government Business Support	**-**	119,600
Other receipts	**-**	8,327
Interest received	**308**	3
Payments to suppliers and employees	**(1,263,201)**	(1,158,171)
Finance costs	**(36)**	(3)
Net cash provided by/(used in) operating activities	**(1,260,647)**	(376,849)
CASH FLOWS FROM INVESTING ACTIVITIES:		
Payment for intangible asset	**(40,912)**	(41,575)
Purchase of property, plant and equipment	**(13,356)**	(2,935)
Payment for deposit	**(4,200)**	-
Net cash used by investing activities	**(58,468)**	(44,510)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Directors' Loans	**-**	1,002,499
Net cash used by financing activities	**-**	1,002,499
Net increase/(decrease) in cash and cash equivalents held	**(1,318,515)**	581,140
Cash and cash equivalents at beginning of year	**1,890,683**	66,215
Cash and cash equivalents at end of the half year	**572,168**	647,355

Notes to the Financial Statements

1: Summary of Significant Accounting Policies

This condensed interim financial report for the reporting period ending 31 December, 2021 has been prepared in accordance with the requirements of the *Corporations Act 2001* and Australian Accounting Standard AASB 134: *Interim Financial Reporting*.

The consolidated interim financial report is intended to provide users with an update on the latest annual financial statements of Analytica Limited. As such it does not contain information that represents relatively insignificant changes occurring during the half year within Analytica Limited. This condensed financial report does not include all the notes normally included in an annual financial report. It is therefore recommended that this financial report be read in conjunction with the annual financial statements of Analytica Limited for the year ended 30 June 2021, together with any public announcements made during the half year.

The same accounting policies and methods of computation have been followed in this interim financial report as were applied in the most recent annual financial statements, other than those outlined in note 1 (f).

The consolidated financial statements have been prepared on an accruals basis and are based on historical costs modified, where applicable, by the measurement at fair value of selected non-current assets, financial assets and financial liabilities.

Significant accounting policies adopted in the preparation of these financial statements are presented below and are consistent with prior reporting periods unless otherwise stated.

The consolidated interim financial report covers Analytica Limited and its controlled entities, PeriCoach Pty. Ltd, Analytica Operations Pty Ltd and Analytica Export ME Pty Ltd. Analytica Limited is a for-profit Company limited by shares, incorporated and domiciled in Australia.

The functional and presentation currency of Analytica Limited is Australian dollars.

The financial report was authorised for issue by the Directors on the date the Directors report was signed.

a. Revenue and other income.

Revenue is measured at the fair value of the consideration received or receivable after taking into account any trade discounts and volume rebates allowed. When the inflow of consideration is deferred, it is treated as the provision of financing and is discounted at a rate of interest that is generally accepted in the market for similar arrangements. The difference between the amount initially recognised and the amount ultimately received is interest revenue.

Revenue from the sale of goods is recognised at the point of delivery as this corresponds to the satisfaction of the performance obligation within the contract.

Interest revenue is recognised using the effective interest method.

Dividend revenue is recognised when the right to receive a dividend has been established.

Dividends received from associates and joint ventures are accounted for in accordance with the equity method of accounting.

Royalty revenue is recognised in the consolidated statement of profit or loss and other comprehensive income when the later of the subsequent sale or usage occurs and the performance obligation to which the sale-based or usage based royalty has been allocated has been satisfied.

The Group is eligible for research and development incentives from the Federal Government. Such amounts are recognised as revenue upon receipt.

All revenue is stated net of the amount of goods and services tax.

b. Inventories

Inventories are measured at the lower of cost and net realisable value. Cost of inventory is determined using the first in first out basis and is net of any rebates and discounts received.

c. Property, plant and equipment

Each class of property, plant and equipment is carried at cost or fair value less, where applicable, any accumulated depreciation and impairment of losses.

Depreciation

Property, plant and equipment, excluding freehold land, is depreciated on a straight line basis over the assets useful life to the Company, commencing when the asset is ready for use.

Leased assets and leasehold improvements are amortised over the shorter of either the unexpired period of the lease or their estimated useful life.

d. Cash and cash equivalents

Cash and cash equivalents comprises cash on hand, demand deposits and short term investments which are readily convertible to known amounts of cash and which are subject to an insignificant risk of change in value.

Bank overdrafts also form part of cash equivalents for the purpose of the interim statement of cash flows and are presented within current liabilities on the interim statement of financial position.

e. Going concern

The financial statements have been prepared on a going concern basis.

The Company has reviewed its forward cash flow projections, which currently indicate the Company will have sufficient cash to conduct its affairs on the assumption that a successful share capital raising undertaking is executed within the next six months. The Company also had a loan facility agreement in place with Dr Monsour up to $400,000 at balance date, however this was increased to $2,000,000 on 29 January 2022. The balance used of this facility at balance date is nil. The term of this facility is set to expire at 30 June 2022, however it is the belief of the Directors that this will be extended for the foreseeable future.

The company also expects to generate sales income during the 2022 year from the sales of its PeriCoach.

On this basis, the Directors believe it is appropriate to prepare the financial statements on a going concern basis.

However, if adequate capital raising is not achieved the company may be unable to continue as a going concern. No adjustments have been made relating to the recoverability and classification of recorded assets amounts and classification of liabilities that might be necessary should the company not continue as a going concern.

f. Adoption of new and revised accounting standards

The Group has adopted all of the new and revised Standards and Interpretations issued by the Australian Accounting Standards Board (the AASB) that are relevant to its operations and effective for an accounting period that begins on or after 1 July 2021.

The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the Company.

Any new, revised or amending Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

2. Result for the half year

Revenue from continuing operations

	Dec-21 $	Dec-20 $
Sales Revenue	**2,882**	-
Government Business Support	**-**	119,600
Grant Income	**-**	653,395
Investment revenue	**308**	3
Royalty Income/(Reversal)	**(1,823)**	8,327
Total Income	**1,367**	781,325

Expenditure

Profit before income tax from continuing operations includes the following specific expenses

Administration expense		
Administration - compliance	**304,324**	297,824
Administration - employment	**188,851**	148,492
Administration - general	**7,088**	6,180
Total Administration expense	**500,263**	452,496
Depreciation, amortisation and impairments		
Intangible assets	**4,987**	1,986
Property, plant and equipment	**2,028**	1,358
Total Depreciation, amortisation and impairments	**7,015**	3,344
Finance expenses		
Directors' Loan	-	25,527
External	**36**	4
Total Finance expenses	**36**	25,531
Marketing expenses		
Marketing - employment	**569**	680
Marketing - Other	-	1,300
Marketing - PeriCoach	**117,777**	35,631
Total Marketing expenses	**118,346**	37,611
Patent maintenance expenses		
Patent Maintenance - AutoStart Burette	**8,758**	4,786
Patent Maintenance - PeriCoach	**4,662**	4,426
Total Patent maintenance expenses	**13,420**	9,212
Research and development expense		
R & D - Employment	**351,111**	307,791
R & D - PeriCoach	**378,622**	391,039
Total Research and development expense	**729,733**	698,830

3. Issued Capital

	Dec-21	Jun-21
	$	$
Ordinary shares: 4,613,801,129 (Jun 2021: 4,613,801,129)	**107,383,796**	107,383,796

(a) Ordinary shares

	Dec-21	Jun-21
	No.	No.
At the beginning of the reporting period	**4,613,801,129**	3,519,612,332
Shares issued during the period	-	1,094,188,797
At the end of the reporting period	**4,613,801,129**	4,613,801,129

4. Operating Segments

Segment information

Identification of reportable segments

The Group has identified its operating segments based on the internal reports that are reviewed and used by the Board of Directors (chief operating decision makers) in assessing performance and determining the allocation of resources.

The Group is managed primarily on the basis of product category and service offerings as the diversification of the group's operations inherently have notably different risk profiles and performance assessment criteria. Operating segments are therefore determined on the same basis.

Reportable segments disclosed are based on aggregating operating segments where the segments are considered to have similar economic characteristics and are also similar with respect to the following:

- the products sold and/or services provided by the segment;
- the manufacturing process;
- the type or class of customer for the products or services;
- the distribution method; and
- any external regulatory requirements.

Performance is measured based on segment profit before income tax as included in the internal financial reports.

Types of products and services by reportable segment

(i) Medical Devices

- AutoStart Burette
- PeriCoach (Perineometer)

Analytica's lead product is the Perineometer device branded PeriCoach, to assist women and their clinicians in treatment of Stress Urinary Incontinence. The PeriCoach has a TGA ARTG entry, CE-marking, and USFDA 510(k) 'approval'.

Analytica is also commercialising the Enhanced Infusion System. The Enhanced Infusion System set automatically restarts the delivery of intravenous fluid once the burette has dispensed its predetermined amount of liquid or drug. Automatic restart of the IV fluid, once the drug is dispensed can provide enormous savings in nursing time during and following a medication event, and reduces the risk of blood clots forming that may obstruct the intravenous cannula. The AutoFlush feature uses the existing IV line to flush syringe and injection port, reducing time, cost and risk.

The Enhanced Infusion System has a TGA ARTG entry and USFDA 510(k) clearance.

(ii) Corporate

The corporate segment includes all other operations including the administration and associated listed public company expenditure.

Basis of accounting for purposes of reporting by operating segments

(a) Accounting policies adopted

Unless stated below, all amounts reported to the Board of Directors, being the chief operating decision maker with respect to operating segments, are determined in accordance with accounting policies that are consistent to those adopted in the annual financial statements of the Group.

Income tax expense

Income tax expense is calculated based on the segment operating net profit using a notional charge of 25%. The effect of taxable or deductible temporary difference is not included for internal reporting purposes.

(b) Segment assets

Where an asset is used across multiple segments, the asset is allocated to the segment that receives the majority of economic value from the asset. In the majority of instances, segment assets are clearly identifiable on the basis of their nature and physical location.

(c) Segment liabilities

Liabilities are allocated to segments where there is direct nexus between the incurrence of the liability and the operations of the segment. Borrowings and tax liabilities are generally considered to relate to the Group as a whole and are not allocated. Segment liabilities include trade and other payables and certain direct borrowings.

Segment performance	Medical Devices		Corporate		Total	
	Dec-21	Dec-20	Dec-21	Dec-20	Dec-21	Dec-20
	$	$	$	$	$	$
REVENUE						
Revenue from customers	2,882	-	-	-	2,882	-
Grant revenue	-	-	-	653,395	-	653,395
Government Business Support	-	-	-	119,600	-	119,600
Royalties	(1,823)	8,327	-	-	(1,823)	8,327
Interest revenue	-	-	308	3	308	3
Total segment revenue	1,059	8,327	308	772,998	1,367	781,325
Depreciation & amortisation	(4,987)	(1,986)	(2,028)	(1,358)	(7,015)	(3,344)
Cost of sales	(1,323)	-	-	-	(1,323)	-
Interest expense	-	-	(36)	(25,531)	(36)	(25,531)
Marketing	(118,346)	(37,611)	-	-	(118,346)	(37,611)
Other expense	-	-	(504,611)	(456,362)	(504,611)	(456,362)
Patent maintenance	(13,420)	(9,212)	-	-	(13,420)	(9,212)
Research & development	(729,733)	(698,830)	-	-	(729,733)	(698,830)
Total segment expense	(867,809)	(747,639)	(506,675)	(483,251)	(1,374,484)	(1,230,890)
Segment profit (loss)	(866,750)	(739,312)	(506,367)	289,747	(1,373,117)	(449,565)
(e) Segment assets						
Segment assets	553,875	482,968	646,077	737,278	1,199,952	1,220,246
Financial assets at fair value through profit and loss	-	-	21,939	10,447	21,939	10,447
Total	553,875	482,968	668,016	747,725	1,221,891	1,230,693
(f) Segment liabilities						
Segment liabilities	-	-	503,164	1,686,502	503,164	1,686,502

5. Contingencies

In the opinion of the Directors, the Company did not have any contingencies at 31 December 2021 (30 June 2021: None).

6. Related Parties

Transactions between related parties are on normal commercial terms and conditions no more favourable than those available to other parties unless otherwise stated.

Transactions occurred with related parties are shown below.

Loan facility to the company up to $400,000 at balance date (30 June 2021: $400,000), however this was increased to $2,000,000 on 29 January 2022, provided by Dr Monsour.

The balance as at reporting date is nil (30 June 2021: nil), Interest of 8.51 % is being paid on this loan.

7. Events Occurring After the Reporting Date

No other matters or circumstances have arisen since the end of the year which significantly affected or could significantly affect the operations of the Group, the results of those operations, or the state of affairs of the Group in future financial years.

Directors' Declaration

In accordance with a resolution of the directors of Analytica Limited, the directors of the company declare that:

1. the financial statements and notes, as set out on pages 9 to 20, are in accordance with the *Corporations Act 2001* and:

    a. comply with Australian Accounting Standard, AASB 134 *Interim Financial Reporting*; and

    b. give a true and fair view of the financial position as at 31 December 2021 and of the performance for the half year ended on that date of the consolidated group;

2. in the directors' opinion, there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

Directors

Dr Michael Monsour

Mr Ross Mangelsdorf

Dated this 23 February 2022

INDEPENDENT AUDITOR'S REVIEW REPORT
TO THE MEMBERS OF ANALYTICA LIMITED

Report on the Half-Year Financial Report

Conclusion

We have reviewed the half-year financial report of Analytica Limited and its controlled entity (the "Group"), which comprises the consolidated statement of financial position as at 31 December 2021, the consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the half-year ended on that date, a summary of significant accounting policies and other explanatory information, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of the Group does not comply with the *Corporations Act 2001* including:

(a) giving a true and fair view of the Group's financial position as at 31 December 2021 and of its performance for the half-year ended on that date; and

(b) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

Basis for Conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the Auditor's Responsibilities for the Review of the Financial Report section of our report. We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

Material Uncertainty Related to Going Concern

Without modifying our opinion, we draw attention to Note 1(e) to the financial report which indicates that the Group is required to undertake a successful capital raising within the next six months to meet forecasted cash needs. These conditions, along with other matters as set forth in Note 1(e), indicate the existence of a material uncertainty that may cast significant doubt about the ability to continue as a going concern and therefore, the Group may be unable to realise its assets and discharge its liabilities in the normal course of business.

Directors' Responsibility for the Half-Year Financial Report

The directors of the Company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

INDEPENDENT AUDITOR'S REVIEW REPORT
TO THE MEMBERS OF ANALYTICA LIMITED (Continued)

Auditor's Responsibility

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 31 December 2021 and its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Bentleys.

Bentleys Brisbane Partnership
Chartered Accountants

Ashley Carle
Partner
Brisbane, 23 February 2022